BOSTON, Oct. 27 /PRNewswire-FirstCall/ — Solos Endoscopy, Inc.
SNDY) is pleased to announce that the Company generated
revenues during the three months ended September 30, 2010 in the
amount of $134,426 versus $99,710 for the three months ended
September 30, 2009. This was an increase of 34.8% for
the three months during 2010 as compared to 2009.
Despite a down global economy, Solos has been able to increase
its sales transactions due to consistent product orders from the
Company’s current customer base. Over the past twelve months, Solos
has placed an emphasis on promoting and marketing its
MammoView® product line to hospitals and cancer centers.
Revenue for the third quarter was driven by sales from the
MammoView® line as well as strong sales from its standard
product line with increased orders for the Company’s Vascular Clamp
“We completed another strong quarter of sales in 2010,” stated
Bob Segersten, President of Solos Endoscopy, Inc. “Year-to-date, we
have delivered double-digit revenue growth in what continues to be
a challenging economic environment.”
The Company expects to post its full unaudited financial results
for the three months ended September 30, 2010 on the Pink Sheets
OTC Markets website within in the next forty-five days.
Throughout the remainder of 2010, the Company will continue its
new product development for the MammoView® product line. In
addition, Solos plans to achieve market expansion through its
efforts to meet the requirements of the ISO 13485 standard and
ultimately obtain the CE Mark and the permission to sell medical
devices in the European Union and Canada.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose
mission is to develop and market high quality and innovative
instruments for the screening, diagnosis, trea